1887

Abstract

This study aimed to evaluate whether the antibiotic fidaxomicin has activity against (Mtb). 38 fully drug-sensitive Mtb strains and 34 multidrug-resistant tuberculosis (MDR-TB) strains were tested using the microplate alamar blue assay (MABA) method to determine the minimum inhibitory concentrations (MICs) for fidaxomicin and rifampicin. Fidaxomicin has high activity against Mtb and is a potential drug to treat Mtb, and MDR-TB infections in particular.

Funding
This study was supported by the:
  • Tongzhou Yunhe Project (Award YH201917)
    • Principle Award Recipient: GuirongWang
  • Beijing Talents foundation (Award 2018000021223)
    • Principle Award Recipient: GuirongWang
  • National Major Science and Technology Projects of China (Award 2017ZX10302301-003-004)
    • Principle Award Recipient: GuirongWang
  • National Major Science and Technology Projects of China (Award 2017ZX09304009-004)
    • Principle Award Recipient: GuirongWang
  • National Natural Science Foundation of China (Award 32070937)
    • Principle Award Recipient: HaoLi
  • National Natural Science Foundation of China (Award 81703632)
    • Principle Award Recipient: GuirongWang
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001324
2021-02-17
2021-10-28
Loading full text...

Full text loading...

References

  1. WHO Global tuberculosis report; 2020
  2. Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med 2015; 5:a017863 [View Article][PubMed]
    [Google Scholar]
  3. Zhanel GG, Walkty AJ, Karlowsky JA. Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection. Can J Infect Dis Med Microbiol 2015; 26:305–312 [View Article][PubMed]
    [Google Scholar]
  4. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422–431 [View Article][PubMed]
    [Google Scholar]
  5. Boyaci H, Chen J, Lilic M, Palka M, Mooney RA et al. Fidaxomicin jams Mycobacterium tuberculosis RNA polymerase motions needed for initiation via RbpA contacts. Elife 2018; 7:e34823 26 02 2018 [View Article][PubMed]
    [Google Scholar]
  6. Kurabachew M, Lu SHJ, Krastel P, Schmitt EK, Suresh BL et al. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis . J Antimicrob Chemother 2008; 62:713–719 [View Article][PubMed]
    [Google Scholar]
  7. Huang H, Ding N, Yang T, Li C, Jia X et al. Cross-Sectional whole-genome sequencing and epidemiological study of multidrug-resistant Mycobacterium tuberculosis in China. Clin Infect Dis 2019; 69:405–413 [View Article][PubMed]
    [Google Scholar]
  8. Molodtsov V, Scharf NT, Stefan MA, Garcia GA, Murakami KS. Structural basis for rifamycin resistance of bacterial RNA polymerase by the three most clinically important RpoB mutations found in Mycobacterium tuberculosis . . Mol Microbiol 2017; 103:1034–1045 [View Article][PubMed]
    [Google Scholar]
  9. Brandis G, Wrande M, Liljas L, Hughes D. Fitness-compensatory mutations in rifampicin-resistant RNA polymerase. Mol Microbiol 2012; 85:142–151 [View Article][PubMed]
    [Google Scholar]
  10. Comas I, Borrell S, Roetzer A, Rose G, Malla B et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet 2011; 44:106–110 [View Article][PubMed]
    [Google Scholar]
  11. Vargas AP, Rios AA, Grandjean L, Kirwan DE, Gilman RH et al. Determination of potentially novel compensatory mutations in rpoc associated with rifampin resistance and rpob mutations in Mycobacterium tuberculosis clinical isolates from peru. Int J Mycobacteriol 2020; 9:121–137 [View Article][PubMed]
    [Google Scholar]
  12. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341:647–650 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001324
Loading
/content/journal/jmm/10.1099/jmm.0.001324
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error